Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2007, Vol. 110, No. 7, pp. 2610-2619.
Prepublished online as a Blood First Edition Paper on May 16, 2007; DOI 10.1182/blood-2007-01-066209.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Methods and Table
Right arrow All Versions of this Article:
blood-2007-01-066209v1
110/7/2610    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fasseu, M.
Right arrow Articles by Regnault, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fasseu, M.
Right arrow Articles by Regnault, A.
Related Collections
Right arrow Neoplasia
Right arrow Cell Cycle
Right arrow Oncogenes and Tumor Suppressors
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

p16INK4A tumor suppressor gene expression and CD3{epsilon} deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis

Magali Fasseu1, Peter D. Aplan2, Martine Chopin1, Nicolas Boissel3, Jean-Christophe Bories4, Jean Soulier1, Harald von Boehmer5, François Sigaux1, and Armelle Regnault1

1 Institut National de la Santé et de la Recherche Médicale (INSERM) U462, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France; 2 Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; 3 INSERM U662, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France; 4 EA3963-Université Paris 7-Denis Diderot-INSERM, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France; 5 Dana-Farber Cancer Institute, Boston, MA

Inactivation of the CDKN2 genes that encode the p16INK4A and p14ARF proteins occurs in the majority of human T-cell acute lymphoblastic leukemias (T-ALLs). Ectopic expression of TAL1 and LMO1 genes is linked to the development of T-ALL in humans. In TAL1xLMO1 mice, leukemia develops in 100% of mice at 5 months. To identify the molecular events crucial to leukemic transformation, we produced several mouse models. We report here that expression of P16INK4A in developing TAL1xLMO1 thymocytes blocks leukemogenesis in the majority of the mice, and the leukemias that eventually develop show P16INK4A loss of expression. Events related to the T-cell receptor ß selection process are thought to be important for leukemic transformation. We show here that the absence of the pT{alpha} chain only slightly delays the appearance of TAL1xLMO1-induced T-ALL, which indicates a minor role of the pT{alpha} chain. We also show that the CD3{epsilon}-mediated signal transduction pathway is essential for this transformation process, since the TAL1xLMO1xCD3{epsilon}-deficient mice do not develop T-ALL for up to 1 year.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020